公开(公告)号：US20240050564A1

公开(公告)日：2024-02-15

申请号：US18271579

申请日：2022-01-07

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Yu LIU ,  Sarah TANNENBAUM-DVIR

IPC: A61K39/395 ,  A61K31/7048 ,  A61K31/282 ,  A61P35/00

CPC classification number: A61K39/3955 ,  A61K31/7048 ,  A61K31/282 ,  A61P35/00

Abstract: This disclosure provides combination therapy for treating a subject, such as a subject afflicted with lung cancer, such as small cell lung cancer, comprising administering to the subject various combinations of an anti-fucosyl-GM1 antibody, an immunomodulatory agent, such as a PD-1/PD-L1 antagonist, such as an antagonist anti-PD-1 or anti-PD-L1 antibody, carboplatin and etoposide.